Blood Culture Diagnostic Techniques Compared for Human Brucellosis
|
By LabMedica International staff writers Posted on 16 Apr 2014 |

Image: Scanning electron micrograph of Brucella abortus (Photo courtesy of the Czech University of Life Science).
Isolation of the bacteria Brucella is the gold standard in the laboratory diagnosis of brucellosis and as the organism is intracellular, the number of circulating bacteria is usually low.
Three different blood culture methods, the lysis concentration (LC), clot culture and conventional Castaneda blood culture techniques, have been compared for the isolation rate and recovery time in the diagnosis of human brucellosis.
Microbiologists at the Shri B. M. Patil Medical College (Bijapur, Karnataka, India) performed blood cultures by LC, clot culture and conventional method in 169 patients who had antibody titers equal to or greater than 160 international units by the serum agglutination test (SAT).
For the conventional culture technique, the blood specimen was inoculated aseptically into the broth phase of Castaneda's biphasic medium consisting of brain heart infusion agar and broth with Brucella selective supplement (Hi-Media; Mumbai, India). For the LC technique, the mixtures centrifuged and the supernatant was discarded and the sediment was inoculated in the Castaneda's medium, instead of culture plate.
For the clot culture technique, the blood clot was preserved in the sterile screw capped plastic tube with glass beads after removal of serum was used for this method. The clot was disrupted by shaking the tubes on a shaker for 15 minutes and the disrupted clot was then inoculated in Castaneda's medium. The media were incubated at 37 °C with 10% carbon dioxide for a maximum of 30 days. Provisional confirmation and biotyping of the isolate was done by performing slide agglutination test using B. abortus and B. melitensis monospecific antisera (Murex Biotech; Dartford, UK).
Overall blood culture positivity was found to be 24.8% by conventional culture, 34.9% by clot method, and 43.1% by the lysis technique. The mean recovery time by lysis and clot culture techniques was significantly less than conventional method, resulting in an overall difference of nearly six and four days respectively.
The authors concluded that for the isolation of Brucella from blood specimen, LC method is better than conventional Castaneda's method as the isolation rate is high and the recovery time is less. Clot culture is a better option when a second blood sample cannot be obtained for culture. As lysis and clot culture techniques are sensitive, simple and inexpensive and yield earlier results, they can be adapted in the technically and economically deprived areas where automated systems are not feasible. The study was published on March 19, 2014, in the Journal of Laboratory Physicians.
Related Links:
Shri B. M. Patil Medical College
Hi-Media
Murex Biotech
Three different blood culture methods, the lysis concentration (LC), clot culture and conventional Castaneda blood culture techniques, have been compared for the isolation rate and recovery time in the diagnosis of human brucellosis.
Microbiologists at the Shri B. M. Patil Medical College (Bijapur, Karnataka, India) performed blood cultures by LC, clot culture and conventional method in 169 patients who had antibody titers equal to or greater than 160 international units by the serum agglutination test (SAT).
For the conventional culture technique, the blood specimen was inoculated aseptically into the broth phase of Castaneda's biphasic medium consisting of brain heart infusion agar and broth with Brucella selective supplement (Hi-Media; Mumbai, India). For the LC technique, the mixtures centrifuged and the supernatant was discarded and the sediment was inoculated in the Castaneda's medium, instead of culture plate.
For the clot culture technique, the blood clot was preserved in the sterile screw capped plastic tube with glass beads after removal of serum was used for this method. The clot was disrupted by shaking the tubes on a shaker for 15 minutes and the disrupted clot was then inoculated in Castaneda's medium. The media were incubated at 37 °C with 10% carbon dioxide for a maximum of 30 days. Provisional confirmation and biotyping of the isolate was done by performing slide agglutination test using B. abortus and B. melitensis monospecific antisera (Murex Biotech; Dartford, UK).
Overall blood culture positivity was found to be 24.8% by conventional culture, 34.9% by clot method, and 43.1% by the lysis technique. The mean recovery time by lysis and clot culture techniques was significantly less than conventional method, resulting in an overall difference of nearly six and four days respectively.
The authors concluded that for the isolation of Brucella from blood specimen, LC method is better than conventional Castaneda's method as the isolation rate is high and the recovery time is less. Clot culture is a better option when a second blood sample cannot be obtained for culture. As lysis and clot culture techniques are sensitive, simple and inexpensive and yield earlier results, they can be adapted in the technically and economically deprived areas where automated systems are not feasible. The study was published on March 19, 2014, in the Journal of Laboratory Physicians.
Related Links:
Shri B. M. Patil Medical College
Hi-Media
Murex Biotech
Latest Microbiology News
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Channels
Clinical Chemistry
view channel
Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
Acute recreational drug toxicity is a frequent reason for emergency department visits, yet clinicians rarely have access to confirmatory toxicology results in real time. Instead, treatment decisions are... Read more
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read moreMolecular Diagnostics
view channel
AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy
Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read more
New CSF Liquid Biopsy Assay Reveals Genomic Insights for CNS Tumors
Central nervous system (CNS) malignancies pose distinctive diagnostic challenges because tissue-based testing is often infeasible and the blood–brain barrier limits the usefulness of plasma liquid biopsy.... Read more
Group A Strep Molecular Test Delivers Definitive Results at POC in 15 Minutes
Strep throat is a bacterial infection caused by Group A Streptococcus (GAS). It is a leading bacterial cause of acute pharyngitis, particularly in children and adolescents, and one of the most common reasons... Read more
Rapid Molecular Test Identifies Sepsis Patients Most Likely to Have Positive Blood Cultures
Sepsis is caused by a patient’s overwhelming immune response to an infection. If undetected or left untreated, sepsis leads to tissue damage, organ failure, permanent disability, and often death.... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more
AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







